Sanofi is again trimming its oncology pipeline, walking away from an armed-antibody cancer treatment licensed from ImmunoGen as it reshapes its approach to the field.
Alnylam's lead RNAi treatment continued to prevent nerve damage tied to a rare disease in an ongoing Phase II study, paving the path for late-stage development.
Sanofi is suing startup Diagnosia over the publication of information about side effects and drug interactions in its physician decision support software.
Sanofi has reached out to its French neighbor Innate Pharma to collaborate on armed antibody treatments, borrowing the biotech's technology to craft new treatments for cancer and inflammatory disease.
Sanofi plans to manufacture its highly anticipated dengue vaccine in a French facility built specifically for the product. But Sanofi Pasteur's vaccine operation in Swiftwater, PA, is also expanding in preparation for a launch of the vax, which may happen later this year.
Fitch Ratings is raising the flag on pharma M&A. The credit ratings agency says the current spate of dealmaking is putting some pressure on European Big Pharma players.
Sanofi's highly anticipated dengue vaccine is being manufactured in a facility in France built specifically for the product. But expansion is also going on at Sanofi Pasteur's vaccine operation in Swiftwater, PA, in preparation for a launch of the vax which may happen later this year.
Sanofi has news for all of the payers, providers and patients who thought the French drugmaker would discount its newly approved insulin Toujeo to get it established in the market. Think again.
Sanofi says it is "flipping the model" in its launch of the first approved vaccine to treat dengue. It will submit it for approval in dengue-stricken nations rather than first filing regulatory submissions in the U.S. and Europe.
Novo Nordisk says the FDA has accepted its reapplication of its long-acting insulin Tresiba, setting it up for an October decision and a launch yet this year if approved this time around. Execs at Sanofi will certainly be watching the calendar just as closely given that a Tresiba launch will complicate the French drugmaker's efforts to its new long-acting insulin Toujeo established as the clear successor to aging Lantus.